The Biggest Bottlenecks Holding Back Cell and Gene Therapy
Members of the 2026 Power List argue that manufacturing, infrastructure, reimbursement, and investment now pose the greatest challenges
-
1
Limited patient access due to manufacturing capacity, clinical delivery, and reimbursement constraints hampers cell and gene therapy growth.
-
2
Delivery challenges, including slow and complex manufacturing processes, hinder the scalability of cell and gene therapies.
-
3
Fragmentation across biology, manufacturing, and regulatory pathways creates inefficiencies that slow down therapy development.
-
4
Access to capital is a significant bottleneck, as investor confidence has waned following previous overexuberant investments.
-
5
The industry needs to adopt industrial-scale manufacturing practices to improve efficiency and patient access to therapies.
